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Metabolism of the predominant 
human milk oligosaccharide 
fucosyllactose by an infant gut 
commensal
Kieran James  1,2,5, Francesca Bottacini  1,5, Jose Ivan Serrano contreras  3, 
Mariane Vigoureux1, Muireann egan1,2, Mary O’connell Motherway1, Elaine Holmes3,4 & 
Douwe van Sinderen1,2*
A number of bifidobacterial species are found at a particularly high prevalence and abundance in 
faecal samples of healthy breastfed infants, a phenomenon that is believed to be, at least partially, 
due to the ability of bifidobacteria to metabolize Human Milk oligosaccharides (HMos). in the current 
study, we isolated a novel strain of Bifidobacterium kashiwanohense, named APCKJ1, from the faeces 
of a four-week old breastfed infant, based on the ability of the strain to utilise the HMO component 
fucosyllactose. We then determined the full genome sequence of this strain, and employed the 
generated data to analyze fucosyllactose metabolism in B. kashiwanohense APCKJ1. Transcriptomic 
and growth analyses, combined with metabolite analysis, in vitro hydrolysis assays and heterologous 
expression, allowed us to elucidate the pathway for fucosyllactose metabolism in B. kashiwanohense 
APCKJ1. Homologs of the key genes for this metabolic pathway were identified in particular in infant-
derived members of the Bifdobacterium genus, revealing the apparent niche-specific nature of this 
pathway, and allowing a broad perspective on bifidobacterial fucosyllactose and L-fucose metabolism.
Breast-feeding influences neonatal intestinal microbiota development and composition1–3, with significant differ-
ences reported between the gut microbiota of breast-fed infants and their formula-fed counterparts4. It currently 
is believed that Human Milk Oligosaccharides (HMOs) represent some of the most influential components of 
human breastmilk and colostrum in terms of their impact on microbiota composition by acting as a selective 
growth substrate2,3,5, with recent work correlating differences in the neonatal microbiota with variations in HMO 
composition of corresponding mothers milk6. After lactose, HMOs are the most abundant carbohydrate com-
ponent of breastmilk2,7, and are composed of a heterogeneous mix of at least 200 distinct glycan structures8. 
HMOs consist of a lactose moiety linked, through a variety of different glycosidic connections, to L-fucose, sialic 
acid, lacto-N-biose (LNB) or N-acetyllactosamine (LacNAc); the latter two cases creating the tetrasaccharides 
lacto-N-tetraose (LNT) or lacto-N-neotetraose (LNnT), respectively. LN(n)T may be elongated by additional 
LNB or LacNAc residues at the reducing end, and/or may be fucosylated or sialylated at different positions2,8,9. 
HMOs can be viewed as a model prebiotic, since it complies with the definition of the latter as a ‘non-digestible 
food ingredient that beneficially affects the host by selectively stimulating growth and/or activity of one or a lim-
ited number of bacteria in the colon, thereby improving host health10. Recent studies have furthermore shown the 
beneficial properties of HMOs extending to protection against infant-associated gastrointestinal conditions, such 
as Campylobacter and Group B Streptococcal infections, and necrotising enterocolitis (NEC)11.
Bifidobacteria are Gram-positive, anaerobes belonging to the Actinobacteria phylum, and are commonly 
observed as commensal members of the mammalian, avian and insect intestinal tract12. Enrichment of bifidobac-
teria has been observed in the faecal microbiota of breastfed infants13, to whom they are believed to provide an 
array of health benefits5,14–16. The dominance of bifidobacteria in this niche is attributed to the presence of a small 
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number of key species, which are capable of selectively utilising (particular) HMOs as their sole carbohydrate 
source5,8,17,18. These infant-associated species include Bifidobacterium bifidum, Bifidobacterium longum subsp. 
infantis and Bifidobacterium breve. B. bifidum carries out extracellular hydrolysis of complex HMOs, including 
LN(n)T, and fucosylated and sialylated structures, prior to the import and metabolism of (many of) the resultant 
mono- and di-saccharides19–25. B. breve and B. longum subsp. infantis internalise (certain) intact HMO moieties, 
such as LNT, LNnT and LNB, and sequentially degrade them for subsequent metabolism of the generated mono-
saccharides8,19,26–30. Furthermore, B. infantis internalizes and then metabolizes various fucosylated and sialylated 
HMOs31–33.
Bifidobacterium kashiwanohense has been previously isolated from the faeces of neonates34,35, though it is 
not considered a common component of the neonatal gut microbiota. There is little knowledge of this species 
and its metabolic capabilities. The ability of two B. kashiwanohense strains to grow on the HMO components 
2′-fucosyllactose (2′-FL) and 3-fucosyllactose (3-FL) was recently shown, although these strains did not appear 
to metabolize the (fucosyllactose component) L-fucose33. While the presence of fucosylated HMOs in breastmilk 
has been shown to vary greatly, depending on genetic and geographical factors36, fucosylated HMOs are gener-
ally thought to represent ~50–80% of all HMOs found in human breastmilk37. Furthermore, free 2′-FL and 3-FL 
represent between 12–45% and 0.5–3% of the total HMO content, respectively36. 2′-FL (Fucα1-2[Galβ1-4]Glc) 
consists of L-fucose linked by an α1-2 bond to the galactose residue in lactose, while its isomer 3-FL (Fucα1-
3Galβ1-4Glc) consists of L-fucose linked by an α1-3 bond to the glucose moiety in lactose37. The ability to metab-
olize 2′-FL and/or 3-FL is therefore considered to be important for infant gut colonisation38. Of note, FL-utilising 
properties of certain members of bifidobacterial species have a crucial impact on metabolite production and early 
life gut microbiota composition38. Metabolite profiles for B. kashiwanohense following growth on 2′-FL or 3-FL 
suggest that the inability of B. kashiwanohense to grow on L-fucose is due to the lack of two enzymes, L-fucose 
mutarotase and fucose permease33. The latter study, and another recent study39, however, demonstrated L-fucose 
metabolism resulting in the formation of 1,2-propanediol (1,2-PD), during growth on fucosyllactose by B. breve, 
B. longum subsp. infantis and B. longum subsp. suis, which suggests the presence of a common pathway for 
L-fucose metabolism. Notably, trophic interactions between the butyrate-producing gut commensal Eubacterium 
hallii and B. breve and/or B. longum subsp. infantis driven by FL and L-fucose utilisation have recently been 
shown to occur in the gut of infants39. Importantly, E. hallii represents one of the first producers of butyrate in the 
infant gut, while it is also able to convert 1,2-PD to propionate40.
In the current study, we sequenced the genome of B. kashiwanohense strain APCKJ1, isolated from faeces 
of a breastfed infant using 2′-FL as a selective carbohydrate. Employing various approaches we dissected fuco-
syllactose metabolism in APCKJ1, and also identified key genes involved in L-fucose metabolism in B. breve. 
Subsequent bioinformatic analysis revealed the distribution of fucose/fucosyllactose utilisation genes among 
members of the genus Bifidobacterium. This work not only elucidates details of fucosyllactose metabolism in B. 
kashiwanohense, but also allows general insights into bifidobacterial L-fucose metabolism.
Results
Isolation of a novel B. kashiwanohense isolate. A single stool sample from an exclusively breast-fed 
neonate, aged 4 weeks, was employed to isolate 2′-FL-utilising Bifidobacterium isolates. Several Bifidobacterium 
isolates were obtained from this faecal sample, based on their resistance to mupirocin (which selects for bifido-
bacteria41,42) and ability to grow on 2′-FL as the sole carbohydrate source. All assessed isolates were found to 
belong to the species B. kashiwanohense and appeared to be clonal. As this is an infrequently encountered species 
(from infant faecal samples), yet clearly exhibiting an ability to grow on 2′-FL, one of these isolates, designated 
APCKJ1, was selected for further characterisation.
carbohydrate utilisation by B. kashiwanohense APCKJ1. In order to further investigate the carbo-
hydrate utilisation capabilities of B. kashiwanohense APCKJ1, growth assays were carried out for this strain inoc-
ulated in modified de Man Rogosa and Sharpe (mMRS) medium supplemented with 1% (wt/vol) of one of 16 
different sugars, including nine HMOs or HMO-components (Fig. 1). Growth was assessed by measuring the 
OD600nm following 24 hours of anaerobic growth at 37 °C. APCKJ1 was shown to reach its highest level of cell 
density following growth on lactose (OD600nm > 3.0), while also reaching high optical densities following growth 
on the monosaccharides glucose, ribose, sorbitol, as well as the disaccharide melibiose and the trisaccharide 
raffinose. Good growth (final OD600nm > 1.5) was observed for just two of the nine HMO components tested: the 
isomers 2′-FL and 3-FL. This confirmed the observation that APCKJ1 is capable of metabolising 2′-FL as its sole 
carbohydrate source. L-fucose, however, did not support growth of APCKJ1 to any substantial degree, suggesting 
the strain is incapable of metabolizing this sugar when present in the growth medium in its free form.
The cell-free supernatants of APCKJ1 following growth on 2′-FL or 3-FL (or the control carbohydrate lac-
tose) were analysed by High Performance Liquid Chromatography (HPLC) for the presence of specific metabolic 
end-products (Fig. 2). As additional controls we also analysed uninoculated mMRS containing lactose, 2′-FL, 
3-FL or no carbohydrate source. This analysis revealed that growth of B. kashiwanohense APCKJ1 on either 2′-FL 
or 3-FL causes the accumulation of lactate and acetate in the growth medium (Fig. 2), which are known metabolic 
end products of lactose and fucosyllactose metabolism in bifidobacteria33,39,43. Furthermore, a peak was observed 
corresponding to 1,2-PD, which has been put forward as an end product of L-fucose metabolism33,39. These find-
ings indicate that B. kashiwanohense APCKJ1 is not only capable of degrading 2′-FL/3-FL and metabolizing its 
lactose component, but that it also utilises the L-fucose constituent of these HMOs.
General genome features of B. kashiwanohense APCKJ1, and transcriptome analysis during 
growth on 2′-FL or 3-FL. To identify the genes involved in 2′-FL/3-FL metabolism we first sequenced the 
genome of B. kashiwanohense isolate APCKJ1, revealing a 2,445,409-base pair (bp) circular molecule, containing 
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53 tRNA genes and 5 rRNA operons. The G + C content of the genome is 56.19%, with a total of 2,110 pre-
dicted protein encoding sequences (CDS). Scores for the sequencing reads and quality are given in Table S1. 
We then assessed global gene expression by microarray analysis of B. kashiwanohense APCKJ1 when grown in 
mMRS supplemented with 2′-FL, and compared with the transcriptome obtained during growth in mMRS sup-
plemented with sorbitol or with lactose. Genes that were shown to be significantly up- or down-regulated in 
transcription above the designated cut-off (fold-change > 5.0, P < 0.001) are shown in Table 1. A fold-change of 
5.0 was chosen as the threshold for differential expression, as this allowed a clear resolution between genes that 
exhibit a high level of increased transcription and (a large number of) genes eliciting a lower level of increased 
transcription, which was presumed to be due to background variation. When grown on 2′-FL (and compared 
Figure 1. Carbohydrate utilization profiles of B. kashiwanohense APCKJ1. Final OD600nm values after 24 hours 
of growth of B. kashiwanohense APCKJ1 in modified MRS containing a range of carbohydrates at 1% (wt/vol) 
as the sole carbon source. The results are mean values obtained from two separate experiments. Error bars 
represent the standard deviation. Figure adapted from thesis Figure 5.1; James, 201897.
Figure 2. Fermentation of lactose, 2′-FL and 3-FL by B. kashiwanohense APCKJ1. HPLC chromatogram 
profiles of fermentations of mMRS containing 1% lactose, 1% 2′-FL or 1% 3-FL inoculated with B. 
kashiwanohense APCKJ1, following 24 hours growth anaerobically at 37 °C, as well as a blank mMRS control. 
Figure adapted from thesis Figure 5.2; James, 201897.
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to the transcriptome of the strain when grown on sorbitol or lactose), the transcriptionally upregulated genes 
of strain APCKJ1 included all genes (with the exception of a predicted regulator, fumR) of a gene cluster corre-
sponding to locus tags BKKJ1_2069-2079 (and designated here as the fum locus [for fucose metabolism]) (Table 1 
and Fig. S1). This gene cluster was found to contain two predicted and adjacent α-fucosidase-encoding genes, 
BKKJ1_2069 and BKKJ1_2070 (designated fumA1 and fumA2, respectively). Microarray analysis also revealed 
that transcription of lacA, encoding a predicted β-galactosidase, and the adjacent lacS, encoding a predicted lac-
tose permease, was increased when cells were grown in a medium containing 2′-FL and compared to transcrip-
tion patterns when grown on sorbitol or lactose, respectively. The lacA and lacS gene cluster correspond to locus 
tags BKKJ1_2066 and 2067, respectively, and are located adjacent to the fum cluster. Based on their annotations, 
the lac genes and the fum gene cluster are predicted to function in lactose and fucosyllactose/L-fucose metabo-
lism, respectively.
Interestingly, when comparing the transcriptomes of a 2′-FL versus lactose-grown APCKJ1 culture, significant 
transcriptional upregulation was noted of gene BKKJ1_0429 (designated here as fumG), predicted to encode 
1,2-PD oxidoreductase. 1,2-PD has previously been identified as a product of L-fucose metabolism in certain 
bifidobacteria33,39, and the presence of this gene is consistent with the results of the fermentation product analysis 
which suggests the utilisation of L-fucose derived from 2′-FL/3-FL by APCKJ1. Between the lacAS genes and the 
fum gene cluster we detected an apparently truncated LacI-type repressor-coding gene, lacR (Table 1).
Comparison of the transcriptomes of a 2′-FL versus sorbitol grown APCKJ1 culture revealed downregulation 
of three distinct gene clusters (with locus tags BKKJ1_0067-0069, BKKJ1_0206-0208 and BKKJ1_0336-0341), 
which, as expected, appear to be involved in sorbitol metabolism based on BLAST analysis (Table 1).
Similar results were obtained when we performed transcriptome analyses for B. kashiwanohense APCKJ1 
grown on 3-FL (available in the GEO dataset provided here).
Gene ID Gene name Function
2′-FL vs 
Sorbitol
2′-FL vs 
Lactose
BKKJ1_0067 BKKJ1_0067 ABC transporter substrate-binding protein −8.12 —
BKKJ1_0068 BKKJ1_0068 ABC transporter permease −5.91 —
BKKJ1_0069 BKKJ1_0069 ABC transporter permease −5.71 —
BKKJ1_0206 BKKJ1_0206 6-phosphogluconate dehydrogenase −13.31 —
BKKJ1_0207 BKKJ1_0207 hypothetical protein −17.67 —
BKKJ1_0208 BKKJ1_0208 putative gluconokinase −17.21 —
BKKJ1_0336 BKKJ1_0336 hypothetical protein −16.99 —
BKKJ1_0338 BKKJ1_0338 hypothetical protein −27.69 —
BKKJ1_0339 BKKJ1_0339 xylitol (sorbitol) dehydrogenase −34.61 —
BKKJ1_0340 BKKJ1_0340 transcriptional regulator −36.34 —
BKKJ1_0341 BKKJ1_0341 aldehyde-alcohol dehydrogenase 2 −22.03 —
BKKJ1_0429 fumG L-1,2-propanediol oxidoreductase — 5.90
BKKJ1_2066 lacS galactoside symporter — 5.35
BKKJ1_2067 lacA beta-galactosidase 6.47 —
BKKJ1_2068 lacR Truncated LacI-type transcriptional regulator — —
BKKJ1_2069 fumA1 GH95 alpha-1 3/4-fucosidase 7.45 6.88
BKKJ1_2070 fumA2 GH29 alpha-1 3/4-fucosidase 11.04 10.43
BKKJ1_2071 fumB L-fucose mutarotase 12.80 12.17
BKKJ1_2072 fumF L-2-keto-3-deoxy-fuconate aldolase 13.14 10.86
BKKJ1_2073 fumD L-fuconolactone hydrolase 14.15 8.21
BKKJ1_2074 fumC L-keto-3-deoxy-fuconate-4-dehydrogenase 15.95 15.37
BKKJ1_2075 fumE L-fuconate dehydratase 17.29 13.90
BKKJ1_2076 fumS ABC transporter solute binding protein 19.68 30.20
BKKJ1_2077 fumT1 ABC transporter permease 20.79 22.82
BKKJ1_2078 fumT2 ABC transporter permease 21.89 30.41
BKKJ1_2079 fumR LacI family transcriptional regulator — —
Table 1. B. kashiwanohense APCKJ1 genes that are transcriptionally upregulated during growth in mMRS 
medium supplemented with 2′-FL as the sole carbohydrate, as compared to growth in mMRS supplemented 
with sorbitol. The level of expression is shown as a fold-value of increase in expression on each carbohydrate, 
as compared to a sorbitol or lactose control, with a cut-off of a minimum 5.0-fold increase in expression. 
Microarray data were obtained using B. kashiwanohense APCKJ1 grown on 1% 2′-FL and were compared with 
array data obtained when B. kashiwanohense APCKJ1 was grown on sorbitol or lactose as a control. The cut-off 
point was set at 5.0-fold, with a P value of <0.001. With the - sign are indicated fold values below the cut-off. 
The predicted functions were determined using a combination of BLASTP71, Pfam (http://pfam.xfam.org) and 
KEGG (http://www.genome.jp/kegg/) searches.
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Biochemical characterisation of FumA1 and FumA2, and activity towards 2′-FL and 3-FL. In 
order to investigate the predicted fucosidase activities encoded by fumA1 (BKKJ1_2069) and fumA2 
(BKKJ1_2070), the corresponding FumA1 and FumA2 proteins were purified as His-tagged versions (and desig-
nated here as FumA1His and FumA2His, respectively; see Materials and Methods). FumA1 is an 87.46 kDa pro-
tein belonging to the GH95 family fucosidases, and FumA2 is a 53.59 KDa protein belonging to the GH29 family 
fucosidases. Neither protein sequence contains a predicted signal peptide site, indicating their likely intracellular 
localisation. Assessment of substrate specificity was performed by incubating either FumA1His or FumA2His 
on their own or in combination with 2′-FL or 3-FL, and analysing the reaction products after varying times 
(20 minutes, 1 hour, 4 hours and 24 hours) by High-Performance Anion-Exchange Chromatography with Pulsed 
Amperometric Detection (HPAEC-PAD). Purified FumA1His was shown to fully liberate lactose and L-fucose 
from both 2′-FL (within 20 minutes) and 3-FL (within 4 hours) (Fig. 3), demonstrating hydrolytic activity towards 
both the Fuc-α1-2Gal linkage in 2′-FL and the Fuc-α1-3Glc connection in 3-FL, thus indicating a key role in the 
hydrolysis and utilisation of both sugars. Purified FumA2His was shown to fully cleave 3-FL (within 20 mins), but 
not 2′-FL, into lactose and L-fucose (Fig. 3), demonstrating hydrolytic activity solely towards the Fumα1-3Glc 
residue. These results indicate a high hydrolytic activity and specificity of FumA1His for 2′-FL, and similarly of 
Figure 3. Hydrolysis products of 2′-FL and 3-FL incubated with FumA1His and FumA2His. (A) HPAEC-PAD 
chromatogram profiles of (I) 2′-FL and (II) 3-FL, when incubated in MOPS buffer (pH7) with FumA1His at 
the time-points 0 minutes, 20 minutes, 1 hour, 4 hours and 24 hours. (B) HPAEC-PAD chromatogram profiles 
of (I) 2′-FL and (II) 3-FL, when incubated in MOPS buffer (pH7) with FumA2His at the time-points 0 minutes, 
20 minutes, 1 hour, 4 hours and 24 hours. Figure adapted from thesis Figure 5.4; James, 201897.
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the FumA2His enzyme for 3-FL, with FumA1His also capable of hydrolysing 3-FL, albeit at an apparently low 
rate.
According to our phylogenetic analysis the FumA1 protein is a as GH95 α-fucosidase based on the fact that 
it clusters with other known and characterized GH95 members (Fig. S2). Among these are Blon_2335 from 
Bifidobacterium longum subsp. infantis ATCC 1569744, AfcA from B. bifidum45 and Afc3 from Clostridium 
perfringens46. Of note, GH95 enzymes, also referred as 1,2-α-L-fucosidases (EC 3.2.1.63), specifically tar-
get α-1,2-fucosidic linkages44,46, thus corroborating our observation of FumA1 showing preference towards 
2′-fucosyllactose. In contrast, FumA2 clusters with other previously characterized GH29 α-fucosidases, 
including BT_2970, BT_2192 and BT3798 from Bacteroides thetaiotaomicron VPI-548247–49, Blon_2336 from 
Bifidobacterium longum subsp. infantis ATCC 1569744, TM0306 from Thermotoga maritima50 and Afc2 from 
Clostridium perfrigens46. Previous studies have demostrated that the GH29 family is further divided into two 
sub-families with different substrate specificity24,48. Notably, FumA2 clusters with previously characterized rep-
resentatives of GH29 subfamily B (e.g. BT2192 from B. thetaiotaomicron and Blon_2336 from B. longum subsp. 
infantis) (Fig. S2), indicating that FumA2 is a member of the B subfamily. GH29-B enzymes, also referred as 
1,3-1,4-α-l-fucosidases (EC 3.2.1.111), have been shown to be specifically active towards α1,3/4-fucosidic link-
ages44,48, in line with our finding that FumA2 has preference towards 3-fucosyllactose.
phenotypic analysis of B. breve UCC2003 strains harbouring B. kashiwanohense APCKJ1 genes 
implicated in 2′-FL/3-FL metabolism. It has previously been shown that L-fucose supports rather mod-
erate growth of the infant-associated species B. breve18,51. While some strains of B. breve have been demonstrated 
to metabolize 2′-FL33,52, the majority of studied strains, including UCC2003, cannot use 2′-FL or 3-FL as a sole 
carbon source to any appreciable extent17,18,33. Thus, B. breve UCC2003 is capable of successfully metabolising 
the two individual components that make up fucosyllactose (i.e. lactose and L-fucose), yet not the 2′-FL or 3-FL 
compounds themselves, whereas B. kashiwanohense APCKJ1 is capable of growth on 2′-FL, 3-FL and lactose, 
but not on L-fucose. We therefore elected to heterologously express genes from the B. kashiwanohense APCKJ1 
fum gene cluster, that are predicted to be required for fucosyllactose uptake and hydrolysis in an attempt to con-
fer 2′-FL and/or 3-FL metabolism to B. breve UCC2003. The fumA1 gene was selected because of its ability to 
hydrolyse both 2′-FL and 3-FL (see above), while the fumS, fumT1 and fumT2 genes (corresponding to locus tags 
BKKJ1_2076–2078) were chosen as these genes are predicted to encode the (2′-FL and 3-FL) transporter compo-
nents of the fum locus (Table 1). Accordingly, the fumA1 gene, and the fumS, fumT1 and fumT2-encompassing 
DNA fragment were cloned into two separate vectors, which were then introduced into B. breve UCC2003, gen-
erating strain B. breve UCC2003-fumA1-fumST1T2 (control strains were constructed containing the ‘empty’ 
cloning vectors, see Materials and Methods and below). B. breve UCC2003-fumA1-fumST1T2 was assessed for 
its ability to grow in mMRS supplemented with 2′-FL, 3-FL, L-fucose or a lactose control, as compared to the 
following strains: wild-type UCC2003, B. breve UCC2003-fumA1-pBC1.2, UCC2003-fumST1T2-pNZ44-strepR, 
and wild-type B. kashiwanohense APCKJ1 (Fig.  4). Strains B. breve UCC2003-fumA1-pBC1.2 and 
UCC2003-fumST1T2-pNZ44-strepR were generated and used as negative controls, as each of these strains 
expresses either of the two components predicted as required for 2′-FL/3-FL utilisation fumA1 and fum-
ST1T2 (i.e. fucosidase activity and 2′-FL/3-FL transport, respectively), which are both expressed by B. breve 
UCC2003-fumA1-fumST1T2. Our results demonstrated that wild-type UCC2003, as well as the recombinant 
UCC2003 strains expressing either fumA1 or fumST1T2 on their own, were unable to grow on 2′-FL or 3-FL (final 
OD600nm < 0.5). In contrast, the recombinant UCC2003 strain expressing both fumA1 and fumST1T2 demon-
strated good growth on either 2′-FL or 3-FL (final OD600nm > 2.0), which is comparable with that obtained by 
APCKJ1 grown on either of these substrates (Fig. 4). As expected all of the tested cultures grew to a high cell den-
sity on lactose (OD600nm > 3.0), and none of the strains demonstrated significant growth on L-fucose. Notably, this 
Figure 4. Growth assays of B. breve UCC2003 WT, B. kashiwanohense APCKJ1 WT and recombinant B. breve 
UCC2003-fumA1-fumST1T2 strains in lactose, L-fucose, 2′-FL or 3-FL. Final OD600nm values after 24 hours 
of growth of wild type B. breve UCC2003, wild type B. kashiwanohense APCKJ1 and recombinant B. breve 
UCC2003 strains in modified MRS containing 1% (wt/vol) lactose, L-fucose, 2′-FL or 3-FL as the sole carbon 
source. The results are the mean values obtained from three separate experiments. Error bars represent the 
standard deviation. Figure adapted from thesis Figure 5.5; James, 201897.
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latter result contrasts with previous work which observed the ability of UCC2003 to grow on L-fucose, though at a 
modest level51. However, some L-fucose metabolism by UCC2003 was observed here, based not on growth ability 
but analysis of metabolic end products, as described below.
Thus, the transcriptome data, substrate hydrolysis profiles and growth results of various recombinant strains 
corroborate the notion that in B. kashiwanohense APCKJ1 the fucosidase encoded by fumA1 is specifically 
required for 2′-FL hydrolysis, and capable of hydrolysing 3-FL, while the solute binding protein and two per-
meases encoded by fumS, fumT1 and fumT2, respectively, are responsible for the uptake and internalisation of 
2′-FL and 3-FL. These results also demonstrate the ability of a recombinant B. breve UCC2003-derivative to suc-
cessfully internalise and utilise 2′-FL and 3-FL for growth, with the heterologous and concomitant expression of 
this transport system and fucosidase from B. kashiwanohense APCKJ1.
Analysis of metabolites generated by fucose and fucosyllactose utilisation. NMR spectros-
copy of the supernatants generated during growth of B. kashiwanohense APCKJ1, B. breve UCC2003 or B. breve 
UCC2003-fumA1-fumST1T2 on lactose, L-fucose, 2′-FL or 3-FL, revealed the metabolic end-products of the fer-
mentation of these sugars by these strains. A combination of standard 1D nuclear magnetic resonance spectros-
copy (NMR) and 2D Homonuclear 1H–1H Total Correlation Spectroscopy (TOCSY) and 1H J-resolved (JRES) 
experiments confirmed the presence of a number of metabolites/carbohydrates, including: 1,2-PD, ethanol, 
lactate, acetate, methanol (contaminant of the 3-FL substrate, see below), formate, lactose, fucose, 2′-FL, 3-FL, 
α-glucose and β-glucose (Table 2).
These identified metabolites/carbohydrates were assigned to peaks in the resulting JRES spectra for each sam-
ple, using the TOCSY experiment to identify 1H-1H coupling in the molecules and allowed accurate identification 
and quantification of each individual compound within the analyzed samples. The millimolar concentrations of 
each of these compounds within a given sample, as well as in the medium of the uninoculated controls are repre-
sented in Table 2. For all three strains, growth on lactose resulted in a decrease in the amount of lactose present in 
the samples. This coincided with a substantial increase in the concentration of acetate, and to a lesser extent etha-
nol, lactate and formate, as compared to the uninoculated control containing 1% lactose. Interestingly, while none 
of the strains demonstrated significant growth on L-fucose as a substrate, the metabolite profiles of supernatants 
obtained following incubation of each of the three with this sugar did not match that of the uninoculated control 
containing 1% L-fucose. In particular, the supernatant of the wild type UCC2003 showed a marked decrease in 
the concentration of L-fucose present, with an increase in the levels of acetate and formate and 1,2-PD, as well 
Culture ID 1,2-propanediol Ethanol Lactate Acetate Methanol Formate L-Fucose 2′-FL 3′-FL aGluc
No inoculum 1% lactose ND ND 3.5 mM 3.8 mM ND 1.0 mM ND ND ND 1.3 mM
No inoculum 1% fucose ND ND 3.8 mM 3.7 mM ND 1.0 mM 38.4 mM ND ND 1.3 mM
No inoculum 1% 2′-FL ND ND 3.5 mM 3.7 mM ND 1.0 mM ND 20.47 mM ND 1.3 mM
No inoculum 1% 3-FL ND ND 3.5 mM 3.8 mM 1.3 mM 1.0 mM ND ND 19.8 mM 1.5 mM
No inoculum mMRS only ND ND 3.6 mM 4.0 mM ND 1.0 mM ND ND ND 1.3 mM
B. breve UCC2003 WT 1% 
lactose ND 2.0 mM 6.7 mM 87.0 mM ND 4.0 mM ND ND ND 1.3 mM
B. breve UCC2003 WT 1% 
fucose 20.7 mM 6.7 mM 3.4 mM 25.4 mM ND 19.7 mM 22.1 mM ND ND ND
B. breve UCC2003 WT 
1% 2′-FL ND 1.3 mM 3.4 mM 6.7 mM ND 1.6 mM 0.6 mM 20.4 mM ND 1.2 mM
B. breve UCC2003 WT 
1% 3-FL ND trace 3.4 mM 7.5 mM 1.3 mM 1.6 mM ND ND 20.5 mM 2.0 mM
B. kashiwanohense 
APCKJ1 WT 1% lactose ND 1.7 mM 6.6 mM 91.7 mM ND 3.0 mM ND ND ND 1.5 mM
B. kashiwanohense 
APCKJ1 WT 1% fucose 1.7 mM 2.0 mM 3.3 mM 9.7 mM ND 5.2 mM 36.1 mM ND ND 1.2 mM
B. kashiwanohense 
APCKJ1 WT 1% 2′FL 4.6 mM 3.8 mM 3.4 mM 62.8 mM ND 9.0 mM ND 3.3 mM ND 0.9 mM
B. kashiwanohense 
APCKJ1 WT 1% 3′FL 4.6 mM 2.7 mM 6.0 mM 58.9 mM 1.3 mM 8.0 mM ND ND 3.5 mM 1.3 mM
B. breve UCC2003 fumA1-
fumST1T2 1% lactose ND 7.9 mM 6.0 mM 84.0 mM ND 2.8 mM ND ND ND 1.3 mM
B. breve UCC2003 fumA1-
fumST1T2 1% fucose 9.8 mM 8.6 mM 3.4 mM 14.5 mM ND 10.9 mM 38.3 mM ND ND 1.2 mM
B. breve UCC2003 fumA1-
fumST1T2 1% 2′-FL 5.1 mM 9.0 mM 5.4 mM 61.6 mM ND 12.0 mM 10.8 mM ND ND 1.3 mM
B. breve UCC2003 fumA1-
fumST1T2 1% 3-FL 7.8 mM 9.9 mM 4.0 mM 68.2 mM 1.3 mM 15.0 mM 7.6 mM ND ND 1.3 mM
Table 2. Millimolar (mM) concentrations of metabolites present in the cell-free supernatants of mMRS 
containing 1% lactose, L-fucose, 2′-FL or 3-FL, following 24 hours incubation with B. breve UCC2003 WT, B. 
kashiwanohense APCKJ1 WT, B. breve UCC2003 fumA1-fumST1T2, or with no inoculum (controls). 2′-FL, 
2′-fucosyllactose; 3-FL, 3-fucosyllactose; aGluc, α-glucose; ND, not detected.
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as a small increase in ethanol concentration. The same trend was observed, but to a lesser extent, in the superna-
tants of UCC2003-fumA1-fumST1T2, and even less so, APCKJ1, when incubated in the presence of 1% L-fucose. 
The corresponding metabolite profiles of the supernatants containing 2′-FL and 3-FL were essentially identical, 
except for the difference between signals originating from the two sugars themselves. The supernatants of wild 
type UCC2003 incubated in the presence of 2′-FL or 3-FL showed no decrease in the concentration of either 
sugar, nor the accumulation of additional metabolites, as compared to the uninoculated controls. The super-
natants of APCKJ1 grown on 2′-FL or 3-FL revealed a near-complete depletion of either sugar, with significant 
increases in the concentrations of 1,2-PD, formate, and in particular acetate. The same trend in metabolite pro-
files was observed for the supernatants of UCC2003-fumA1-fumST1T2 grown on either 2′-FL or 3-FL, with full 
depletion of these two sugars. These trends in metabolite profiles between the individual samples were further 
confirmed by PCA analysis, which showed distinct clustering of the B. kashiwanohense APCKJ1 WT and the 
UCC2003-fumA1-fumST1T2 strains with the exception of the isolates grown on fucose, which clustered inde-
pendently regardless of bacterial strain (Fig. S3). The presence of a low level of methanol in all 3-FL-containing 
samples (including the uninoculated control) is presumed to be due to contamination of 3-FL used for these 
experiments with this alcohol.
transcriptome analysis of recombinant B. breve UCC2003 grown on 2′-FL. The results of the 
metabolite analysis indicate that, while neither B. breve UCC2003 nor B. kashiwanohense APCKJ1 are capable of 
efficient growth using L-fucose as a sole carbohydrate source, they both still demonstrate the ability to consume 
a limited quantity of this sugar, and convert it into organic acids and 1,2-PD, in particular (WT) UCC2003. 
However, the genes involved in this metabolic process in B. breve UCC2003 cannot be identified by transcrip-
tomic analysis during this metabolism of free L-fucose, as growth is not sufficient to allow this.
Thus, transcriptomic analyses were carried out on the recombinant B. breve strain generated in this study 
during growth on fucosyllactose, in order to identify the potential genes specifically involved in the metabolism of 
the L-fucose component of fucosyllactose. Global gene expression was determined by microarray analysis during 
growth of UCC2003-fumA1-fumST1T2 in mMRS supplemented with 2′-FL, as compared with gene expression 
during growth in mMRS supplemented with ribose. As lactose is the other constituent of 2′-FL, microarray anal-
ysis was also carried out to compare gene expression during growth of UCC2003-fumA1-fumST1T2 in mMRS 
supplemented with lactose (as compared to gene expression during growth in mMRS supplemented with ribose), 
in order to identify the lactose metabolism-specific genes expressed during the utilisation of fucosyllactose. Genes 
that were shown to be significantly upregulated in transcription above the designated cut-off (fold-change > 2.0, 
P < 0.001) are displayed in Table 3. A fold-change of 2.0 was chosen as the threshold for differential transcription, 
as this allowed a clear resolution of those genes that exhibited the highest level of increased transcription (from a 
presumed background of a high number of genes that elicit a lower level of increased transcription).
Among the genes that showed increased transcription when UCC2003-fumA1-fumST1T2 was grown on lac-
tose or 2′-FL were genes from loci known to function in lactose metabolism, namely the lnt (Bbr_0526-0530)30 
and lac loci (Bbr_1551-1553)53. Among the genes that were uniquely upregulated in transcription during growth 
on 2′-FL were those of the gene cluster Bbr_1739-1748 (containing genes, homologs of which are also present 
Gene ID
Gene 
name Function 2′-FL Lactose
Bbr_0526 lntR LacI transcriptional regulator — —
Bbr_0527 lntP1 ABC transporter permease 2.61 3.81
Bbr_0528 lntP2 ABC transporter permease 3.35 2.12
Bbr_0529 lntA GH42 Beta-galactosidase 2.48 2.21
Bbr_0530 lntS ABC transporter solute binding protein — —
Bbr_1551 lacS Galactoside symporter 18.72 22.27
Bbr_1552 lacZ6 GH2 Beta-galactosidase 12.98 9.05
Bbr_1553 lacI LacI transcriptional regulator — —
Bbr_1740 fumF L-2-keto-3-deoxy-fuconate aldolase 4.16 —
Bbr_1741 fumD L-fuconolactone hydrolase 4.69 —
Bbr_1742 fumP L-fucose permease 4.49 —
Bbr_1743 fumC L-keto-3-deoxy-fuconate-4-dehydrogenase 3.70 —
Bbr_1744 fumE L-fuconate dehydratase 7.12 —
Bbr_1745 fumR LacI transcriptional regulator — —
Table 3. B. breve UCC2003-fumA1-fumST1T2 genes that were transcriptionally upregulated during growth in 
mMRS medium supplemented with 2′-FL or lactose as the sole carbohydrate, as compared to growth in mMRS 
supplemented with ribose. The level of expression is shown as a fold-value of increase in expression on each 
carbohydrate, as compared to a ribose control, with a cut-off of a minimum 2.0-fold increase in expression. 
Microarray data were obtained using B. breve UCC2003-fumA1-fumST1T2 grown on 1% 2′-FL or lactose and 
were compared with array data obtained when B. breve UCC2003-fumA1-fumST1T2 was grown on ribose as a 
control. The cut-off point was set at 2.0-fold, with a P value of <0.001. With the - sign are indicated fold values 
below the cut-off. The predicted functions were determined using a combination of BLASTP71, Pfam (http://
pfam.xfam.org) and KEGG (http://www.genome.jp/kegg/) searches.
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in the fum locus of APCKJ1) (Table 3 and Fig. S1). These results indicate that while expression of the non-native 
B. kashiwanohense APCKJ1 genes fumA1, fumS, fumT1 and fumT2 in B. breve UCC2003 allows the latter strain 
to take up 2′-FL and to hydrolyse it into lactose and L-fucose, expression of native UCC2003 genes of the lnt, 
lac and fum loci are presumed to enable strain UCC2003-fumA1-fumST1T2 to further metabolise the released 
carbohydrates.
Elucidation of the fucosyllactose/fucose metabolic pathway in B. kashiwanohense and B. 
breve. The results of the APCKJ1 transcriptome analyses indicate involvement of the fum locus and fumG 
in fucosyllactose metabolism, and the combined results of the in vitro hydrolytic assays and recombinant 
UCC2003 growth analysis implicate the APCKJ1 fucosidase-encoding genes fumA1 and fumA2, as well as the 
transporter-encoding genes fumS, fumT1 and fumT2 in the internalisation and hydrolysis of 2′-FL and 3-FL. 
However, the presence of further genes of the fum locus, as well as fumG, upregulated in transcription during 
growth on 2′-FL or 3-FL suggests the involvement of these genes in the metabolism of the liberated L-fucose, 
given that the genes for lactose metabolism appear to be constitutively expressed in strain APCKJ1. Likewise, 
transcriptional upregulation of genes in the UCC2003 fum locus during growth of the recombinant strain on 
2′-FL implicate these genes in L-fucose metabolism in UCC2003. This, and the NMR data, suggests that both 
B. kashiwanohense APCKJ1 and B. breve UCC2003 possess functional pathways for the metabolism of L-fucose.
A pathway for the anaerobic catabolism of L-fucose leading to the formation of 1,2-PD (via 
non-phosphorylated intermediates) has recently been proposed for B. longum subsp. infantis ATCC1569733, 
based on sequence homology with enzymes from a fucose-dependent metabolic route previously identified in 
Xanthomonas campestris54. Genes involved in the proposed L-fucose utilisation pathway in B. longum subsp. 
infantis ATCC15697 were used in BLASTP searches for homologs in the genomes of B. kashiwanohense APCKJ1 
and B. breve UCC2003. Homologs identified in the APCKJ1 and UCC2003 genomes, whose predicted anno-
tations did not match the annotations of their ATCC15697 equivalents (based on their function in the fucose/
fucosyllactose utilisation pathways33), were further checked for alternative annotations in the Pfam (http://pfam.
xfam.org) and KEGG (http://www.genome.jp/kegg/) databases.
This search revealed the presence of homologs for all predicted fucose utilisation genes from ATCC15697 in 
APCKJ1 (Table S2), including seven of the genes of the fum locus, and the gene fumG, all of which were transcrip-
tionally upregulated when APCKJ1 was grown on 2′-FL (see above). These results therefore suggest the presence 
of all genes necessary for L-fucose metabolism in B. kashiwanohense APCKJ1, via a pathway converting L-fucose 
into L-2-keto-3-deoxyfuconate (as proposed in B. breve, B. longum subsp. infantis, and B. longum subsp. suis33,39), 
but subsequently converted into L-lactaldehyde and pyruvate by means of a predicted L-2-keto-deoxy-fuconate 
aldolase (FumF) encoded by the fum locus (Fig. 5). The presence of an L-1,2-propanediol oxidoreductase (FumG) 
Figure 5. Fucose utilisation pathway in B. kashiwanohense and B. breve. Schematic representation of the 
pathway for the utilisation of fucosyllactose in B. kashiwanohense APCKJ1 (red arrows) and B. breve UCC2003 
(grey arrows). Figure adapted from thesis Figure 5.6; James, 201897.
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in the genome sequence of APCKJ1 allows the further reduction of L-lactaldehyde into L-1,2-PD (Fig. 5). These 
findings are supported by the observed accumulation of lactate, acetate, formate (all metabolites of pyruvate) and 
1,2-PD in the 2′-FL and 3-FL fermentates analysed by HPLC and NMR, as mentioned above.
Homologs for the fum genes in APCKJ1 were identified in the UCC2003 genome (Table S2) and were shown to 
be transcriptionally upregulated when the recombinant B. breve UCC2003 was grown on 2′-FL (Table 3). Notably, 
a recent transcriptional study conducted on B. breve UCC2003 identified the FumG homologue (Bbr_1505) as 
constitutively expressed in this strain55.
The ATCC15697 genes lacking homologs in UCC2003 were the GH29 α-fucosidase-encoding gene and 
the L-fucose mutarotase-encoding gene, as well as those encoding the components the (three) components of 
the proposed fucosyllactose uptake system. While neither B. breve UCC2003 nor B. kashiwanohense APCKJ1 
demonstrated significant growth on free L-fucose, our NMR data indicate active metabolism of this sugar in both 
species, generating the same metabolites (although at lower levels) as are observed following growth on 2′-FL or 
3-FL. Thus, the apparent absence of an L-fucose mutarotase does not seem to prevent metabolism of L-fucose in 
UCC2003. While a GH95 fucosidase-encoding gene homologous to fumA1kw (Bbr_1288) was identified within 
an additional “HMO islet” in UCC2003 (Bbr_1288-91) (Fig. 6), the presence of 2′-FL or 3-FL do not seem to 
induce transcription of this region, as demonstrated in the recombinant UCC2003 fumA1-ST1T2 growth assays. 
It is possible that this locus containing fumA1br targets other fucosylated HMO structures, such as fucosyl-LN(n)
T, as B. breve is known to efficiently consume free LN(n)T30. Alternatively, it may be that this is a non-functional 
remnant of a former FL-utilization gene cluster.
Distribution of fucose/fucosyllactose utilisation genes in the Bifidobacterium genus. The results 
of the microarray analysis implicated the protein products of fumG (BKKJ1_0429) as well as the genes of the fum 
locus (BKKJ1_2069-2079) in the utilisation of fucosyllactose by B. kashiwanohense APCKJ1. This is supported by the 
results of the phenotypic analysis of the B. breve UCC2003 strain expressing the fucosidase FumA1 and associated 
transporter proteins encoded by this locus. We selected four genes within the fum locus responsible for the intra-
cellular metabolism of fucosyllactose and/or L-fucose identified in APCKJ1 in order to observe their distribution 
within the Bifidobacterium genus. The regulatory and transport-associated genes of the fum locus were excluded 
from comparative analysis, as carbohydrate transporter and transcriptional regulation-associated genes generally 
share a high degree of homology across bifidobacteria, thus lacking distinguishable sequence variability56,57.
This analysis revealed that the four genes included in the analysis are predominant across infant-associated 
bifidobacteria (e.g. B. kashiwanohense, B. breve, B. longum subsp. infantis and B. pseudocatenulatum), with the 
exception of B. bifidum. (Fig. 7). This corroborates the observation that members of the species B. bifidum employ 
extracellular fucosidases to liberate the lactose component of 2′-FL and 3-FL, which is subsequently metabolised, 
Figure 6. Fucose utilisation loci in infant-derived bifidobacterial strains. Comparison of the fucose/
fucosyllactose metabolism genes of B. kashiwanohense APCKJ1 with corresponding homologous loci of B. 
longum subsp. infantis ATCC 15697, B. pseudocatenulatum DSM 20438 and B. breve UCC2003, as identified 
using the heatmap in Fig. 7. Each solid arrow represents an open reading frame. The length of each arrow 
is proportional to the size of the open reading frame, and the color code is indicative of the predicted gene 
function. The amino acid sequence identity of each predicted protein expressed as a percentage is also shown.
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but are not capable of metabolising the released L-fucose58. The degree of similarity between the fucose utilisation 
genes from B. kashiwanohense APCKJ1 and their corresponding homologous loci in B. longum subsp. infantis 
ATCC15697 and B. breve UCC2003 are shown in Table S2.
Figure 7. Distribution of fum genes across the Bifidobacterium genus. Heatmap representing the distribution 
of homologs of four genes encoding proteins predicted to have a key role in fucose/fucosyllactose utilisation 
pathway from B. kashiwanohense APCKJ1 across the Bifidobacterium genus. Gene products from the 
representative type strain genomes of all online-available Bifidobacterium species with a significant homology 
of 50% iterative similarity over 50% of protein length are represented in the matrix. The colour code grading 
represents the degree of sequence similarity at protein level, with the species grouped by origin of isolation.
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Discussion
B. kashiwanohense represents an example of an apparently infant-specific Bifidobacterium species, although just 
two publications have previously reported on the isolation of this species from infant faeces34,35. The bifidobac-
terial component of the infant gut microbiota is typically dominated by the species B. breve, B. longum subsp. 
longum and B. bifidum, with B. pseudocatenulatum, B. longum subsp. infantis and B. longum subsp. suis occurring 
at lower frequency13,59–61. However, the ability of members of B. kashiwanohense to utilise milk-derived substrates 
suggests that the infant gut may constitute its primary ecological niche. The ability of a B. kashiwanohense isolate 
to grow on the HMOs 2′-FL or 3-FL as its sole carbohydrate source has been reported33. HMO utilisation by 
certain members of the Bifidobacterium genus appears to be present in some infant-associated species8,18,19,29,33. 
As fucosylated sugars typically represent a substantial proportion of all HMOs2,36,37, the ability to utilise fucosyl-
lactose by B. kashiwanohense represents a specific adaptation to the neonatal gut environment. Here, a novel B. 
kashiwanohense strain (APCKJ1) isolated from the faeces of a breastfed infant demonstrated the ability to con-
sume 2′-FL or 3-FL as its sole carbohydrate source, which became the focus of this investigation.
Transcriptional analysis of APCKJ1 revealed an 18 kb gene cluster dedicated to the metabolism of fucosyllac-
tose. This region contains the adjacent lac and fum loci, thus representing a potential ‘HMO island’ conferring 
the ability to utilize fucosyllated HMOs. Interestingly, the constitutive transcription of the lac locus (Table 1) is 
due to the presence of a truncated, non-functional LacI-type repressor (LacR) in APCKJ1 strain. Furthermore, 
homologs of lacR appear to be entirely absent in B. kashiwanohense DSM21854 and B. longum subsp. infan-
tis ATCC1569733. A homolog of this ‘HMO island’ has been previously described in B. longum subsp. infan-
tis26,62,63 and B. longum subsp. longum64, thus reinforcing the notion of specific adaptations to HMO utilisation by 
infant-associated bifidobacteria.
The combined results of in vitro hydrolysis assays, heterologous expression of FumA1 and FumA2 fucosidases 
in B. breve UCC2003, as well as growth results obtained with recombinant UCC2003 strains confirmed the pre-
dicted functions of some of the genes of the fum locus. Our findings are consistent with the notion that the three 
adjacent genes fumS, fumT1 and fumT2 encode transport components necessary for 2′-FL/3-FL uptake, while the 
fumA1 and fumA2 encoded fucosidases are responsible for the hydrolysis of 2′-FL and 3-FL, respectively. Of note, 
our findings corroborate what had previously been observed in a subset of FL-utilising bifidobacteria (members 
of B. breve, B. longum and B. pseudocatenulatum spp), where a solute binding protein of an ABC transporter 
system and an α-fucosidase (GH95 family) were shown to play an essential role in FL utilisation38. Interestingly, 
while FumA1 is capable of hydrolysing both 2′-FL and 3-FL, it possesses higher catalytic efficiency with the for-
mer; FumA2 instead can only hydrolyse 3-FL. Such apparent redundancy in the degradation of isomeric HMO 
structures is not unusual in bifidobacteria19,27,30. However, it is interesting that both FumA1 and FumA2 can 
hydrolyse 3-FL, as this HMO has been reported to be much less abundant in breastmilk compared to its isomer 
2′-FL36. We can’t exclude that the true target substrate for FumA2 may be in fact another fucosylated HMO, such 
as fucosyl-LN(n)T, containing similar linkages.
While these results reveal the mechanisms of fucosyllactose uptake and intracellular hydrolysis in B. kashiwan-
ohense APCKJ1, they do not reveal whether small fractions of L-fucose may be internalised and used by the cell. 
The combined results of the HPLC and NMR analyses of the various 2′-FL/3-FL and L-fucose fermentations, as 
well at the APCKJ1 microarrays, indicate the utilisation of the L-fucose mainly resulting by the hydrolysis of 2′-FL 
and 3-FL, with even some partial metabolism of free L-fucose. The comparative analysis performed between B. 
kashiwanohense APCKJ1 and B. longum subsp. infantis ATCC15697 revealed that all the presumed genetic compo-
nents necessary for the utilisation of L-fucose are encoded by APCKJ1. This therefore represents the first evidence 
of a complete and functional fucose utilisation pathway in B. kashiwanohense, a species which has been previously 
suggested to extracellularly release the fucose component of fucosyllactose33,39. In addition to this we also identified 
an identical (predicted) pathway for L-fucose metabolism in B. breve UCC2003, as this species has recently been 
characterised for its utilisation of L-fucose39. The observed depletion of L-fucose and accumulation of its breakdown 
product 1,2-PD show that B. breve UCC2003 and B. kashiwanohense APCKJ1 possess the ability to at least partially 
metabolise free L-fucose, despite not growing to any significant degree in its sole presence. Interestingly, 1,2-PD 
excretion in human urine and faeces has been largely attributed to contamination since it is an excipient in several 
pharmaceutical preparations or food additives65. However, other research has shown that 1,2-PD is present in higher 
concentrations in faeces of breastfed babies66, which would be consistent with microbial influence.
Identification of homologs involved in fucose metabolism across the Bifidobacterium genus highlights the 
apparent importance of this pathway for colonisation of the infant gut. While the ability to utilise fucosyllac-
tose undoubtedly provides an advantage for B. kashiwanohense establishment in the breastfed neonatal gut, 
this strategy is also employed by other infant-associated bifidobacteria, including B. bifidum, B. longum subsp. 
infantis, B. longum subsp. longum (and possibly B. pseudocatenulatum) as well as some species of B. breve, all of 
which are capable of utilising other HMO components, such as sialyllactose, LN(n)T, LNB, sialic acid and/or 
L-fucose8,19–32,64. Therefore, the narrow specialisation in HMO metabolism by B. kashiwanohense may in fact also 
be a hindrance in becoming one of the dominant species in the breastfed infant gut microbiota.
The findings of this study reinforce the importance of HMO metabolism for the successful proliferation of 
Bifidobacterium species in the breastfed infant gut. This allows the depiction of the metabolic pathway required 
for the utilisation of fucosyllactose by B. kashiwanohense APCKJ1 and a potential pathway for the metabolism 
of free L-fucose by B. breve UCC2003, and furthermore reveals the distribution of fucose-utilisation associated 
genes in Bifidobacterium species typically found in neonates. Our findings not only demonstrate the conservation 
of fucose metabolism in many infant-associated bifidobacteria, but also highlight the role of fucosylated HMOs 
in bifidobacterial establishment in the breastfed infant gut.
Thus, the outcome of our work significantly contributes to increasing our understanding of HMO metabolism 
by infant-associated bifidobacteria. In particular B. kashiwanohense, while previously shown to consume HMO33, 
remained until now uncharacterised for its manner of HMO utilisation. Our findings have generated insights into 
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the pathway employed by a number of Bifidobacterium species for their metabolism of L-fucose freely available or 
liberated by the degradation of larger HMO structures. Ultimately, our gained understanding of HMO metabo-
lism by a number of Bifidobacterium species can be used as a tool to identify infant-specific probiotic strains and 
conversely reinforces the potential of fucosylated HMOs as a prebiotic.
Materials and Methods
Strain isolation from infant faeces, and species identification. Pure cultures of Bifidobacterium 
strains, capable of utilising 2′-FL as their sole carbohydrate source, were isolated from the faeces of an exclusively 
breastfed neonate (aged 4 weeks). The faecal sample was obtained from the APC Microbiome Ireland human 
clinical sample collection (stored at −80 °C), originally collected for the InfantMet Cohort67. Mothers were 
approached for consent between February 2012 and May 2014 at the Cork University Maternity Hospital. All 
mothers provided informed consent for the use of the infant faeces in this study. Ethical approval provided by the 
Cork University Hospital Research Ethics Committee (ethical approval reference: ECM (w) 07/02/2012), with 
all methods performed in accordance with the relevant guidelines and regulations required by said committee. 
Bifidobacterium culture isolates were obtained using a method based on that employed in the InfantMet study67, 
though with the following modifications. All sample preparation and platings were carried out under anaerobic 
conditions in a modular atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 37 °C. One gram 
of frozen faecal sample was thawed anaerobically at 37 °C, and resuspended in 10 ml PBS (Sigma Aldrich, Ireland) 
supplemented with 0.05% L-cysteine hydrochloride (Sigma Aldrich, Ireland). Selection of bifidobacteria was per-
formed by spread-plating 10 aliquots of 1 ml of the faecal resuspension on: modified de Man Rogosa and Sharpe 
(mMRS) agar68, supplemented with 1% (wt/vol) 2′-FL (Glycom A/S, Lyngby, Denmark), 0.05% L-cysteine-HCl, 
100 μg/ml mupirocin (Oxoid, Fannin, Ireland) and 50 units nystatin suspension (Sigma Aldrich, Ireland). Agar 
plates were incubated anaerobically at 37 °C for 72 h. Emerging colonies from these plates were resuspended 
in 1 ml of PBS supplemented with 0.05% L-cysteine-HCl, after which the resuspensions from the 10 plates of 
a single sample were pooled and homogenised, and serial-diluted in the aforementioned PBS, and dilutions 
between 1 × 10−4 and 1 × 10−8 were spread-plated on 2′-FL-supplemented mMRS agar, as described above, and 
incubated anaerobically at 37 °C for 72 h. Single, isolated colonies were selected from the serial dilution plates, 
and re-streaked onto the same agar medium, and incubated anaerobically at 37 °C for 48 h. This sub-cultivation 
process was repeated twice, after which individual colonies were inoculated into modified mMRS medium, sup-
plemented with 1% lactose and 0.05% L-cysteine-HCl. Pure cultures were stocked and stored at −80 °C. Isolates 
were confirmed as bifidobacteria based on the fructose-6-phosphate phosphoketolase activity test69, and species 
identity was determined by sequencing of their ITS region70.
Genome sequencing and annotation of novel isolate Bifidobacterium kashiwanohense 
APCKJ1. Genome sequencing of the B. kashiwanohense isolate was performed by GATC Biotech Ltd. 
(Germany) using Pacific Biosciences SMRT RSII technology. Raw sequencing reads were de novo assembled 
using the Hierarchical Genome Assembly Process (HGAP) protocol RS_Assembly.2 implemented in the SMRT 
Smart Analysis portal v.2.3 with default parameters (https://github.com/PacificBiosciences/SMRT-Analysis). 
Open Reading Frame (ORF) prediction and automatic annotation was performed using Prodigal v2.0 (http://
prodigal.ornl.gov) for gene predictions, BLASTP v2.2.26 (cut-off e-value of 0.0001)71 for sequence alignments 
against a combined bifidobacterial genome-based database, and MySQL relational database to assign annota-
tions. Predicted functional assignments were manually revised and edited using similarity searches against the 
non-redundant protein database curated by the National Centre for Biotechnology Information (ftp://ftp.ncbi.
nih.gov/BLAST/db/) and PFAM database (http://pfam.sanger.ac.uk), allowing a more detailed, in silico char-
acterization of hypothetical proteins. GenBank editing and manual inspection was performed using Artemis 
v18 (http://www.sanger.ac.uk/resources/soft-ware/artemis/). Transfer RNA genes were identified employing 
tRNAscan-SE v1.4 and ribosomal RNA genes were detected based on Rnammer v1.272 software supported by 
BLASTN v2.2.26.
nucleotide sequence analysis and multiple sequence alignment. Sequence data were obtained 
from Artemis-mediated73 genome annotations of B. kashiwanohense strains APCKJ1, JCM1543974 and PV20-275, 
and B. breve UCC200376. Database searches were performed using non-redundant sequences accessible at the 
National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov) using BLAST71. Sequences were 
verified and analysed using SeqMan and SeqBuilder programs of the DNAStar software (version 10.1.2; DNAStar, 
Madison, WI, USA). Multiple sequence alignments of amino acid sequences were created with Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalw/), using default settings77. Alignments were visualised with Genedoc 
v 2.7.0 (http://iubio.bio.indiana.edu/soft/molbio/ibmpc/), using physicochemical display mode (similar colouring 
based on common physical and chemical properties).
Bacterial strains, plasmids, culture conditions and Bifidobacterium growth assays. Bacterial 
strains and plasmids used in this study are listed in Table S3. B. breve and B. kashiwanohense cultures were incubated 
under anaerobic conditions in a modular atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 
37 °C. B. breve UCC2003 was routinely cultured in either de Man Rogosa and Sharpe medium (MRS medium; Difco, 
BD, Le Pont de Claix, France) supplemented with 0.05% L-cysteine-HCl and 1% lactose, or reinforced clostridial 
medium (RCM; Oxoid Ltd., Basingstoke, England). B. kashiwanohense APCKJ1 was routinely cultured in modified 
mMRS supplemented with 0.05% L-cysteine-HCl and 1% lactose. Lactococcus lactis strains were cultivated in M17 
broth (Oxoid Ltd., Basingstoke, England) containing 0.5% glucose78 at 30 °C. Escherichia coli strains were cultured 
in Luria-Bertani (LB) broth79 at 37 °C with agitation. Where appropriate, growth media contained chloramphenicol 
(Cm; 5 μg ml−1 for L. lactis and E. coli, 2.5 μg ml−1 for B. breve) or streptomycin (Strep; 400 μg ml−1).
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Carbohydrate utilisation by bifidobacterial strains was examined in mMRS medium68, and excluding a carbo-
hydrate source. Prior to inoculation, the mMRS medium was supplemented with cysteine-HCl (0.05%, wt/vol) 
and a particular carbohydrate source (1%, wt/vol). It has previously been shown that mMRS does not support 
growth of B. breve UCC2003 in the absence of an added carbohydrate68. Carbohydrates used were lactose, glu-
cose, D-ribose, sorbitol, cellobiose, raffinose, melibiose (all purchased from Sigma Aldrich, Steinheim, Germany), 
and LNT, LNnT, lactosamine-hydrochloride (lactosamine HCl), N-acetylneuramic acid (sialic acid), L-fucose, 
3-sialyllactose (3-SL), 6-sialyllactose (6-SL), 2′-FL and 3-FL (all obtained from Glycom, Lyngby, Denmark). A 
1% wt/vol carbohydrate concentration was considered sufficient to analyse growth capabilities of a strain on 
a particular carbon source. To determine bacterial growth profiles and final optical densities, 5 ml of freshly 
prepared mMRS medium, including a particular carbohydrate (see above), was inoculated with 50 μl (1%) of 
a stationary phase culture of B. breve UCC2003 or B. kashiwanohense APCKJ1. Uninoculated mMRS medium 
was used as a negative control. Cultures were incubated anaerobically at 37 °C for 24 h, and the optical density at 
600 nm (OD600nm) was determined manually. Growth assays were repeated in duplicate or triplicate, depending 
on carbohydrate availability.
HPLC analysis. Fermentation end-product profiles were assessed by HPLC following growth of selected 
bifidobacteria in mMRS medium containing 1% 2′-FL, 3-FL or lactose as the sole carbohydrate source. Collected 
culture samples were then prepared for HPLC analysis by centrifugation at 3270 × g for 5 min, after which the 
resulting supernatants were filter sterilized (0.45 μm filter, Costar Spin-X Column) and stored at −20 °C until fur-
ther use. An Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA) with a refractive index detector 
was used to detect generated metabolites. Metabolite peaks were identified based on retention times of known 
standards (2′-FL, 3-FL, L-fucose, lactose, lactic acid, acetic acid, formic acid, sodium pyruvate and 1,2-PD) at 
a concentration of 10 mM. Non-fermented mMRS medium containing carbohydrates (or the absence of any 
carbohydrate) served as controls. A REZEX 8 μm 8% H organic acid column (300 mm × 7.8 mm, Phenomenex, 
Torrance, CA, USA) was utilized and maintained at 65 °C. Elution was performed for 25 min using a 0.01 M 
H2SO4 solution at a constant flow rate of 0.6 mL/min.
Analysis of global gene expression using B. breve DnA microarrays. Global gene transcription 
was determined during log-phase growth of B. kashiwanohense APCKJ1 in mMRS supplemented with 2′-FL. The 
obtained transcriptome was compared to that determined for log-phase B. kashiwanohense APCKJ1 cells when 
grown in mMRS supplemented with sorbitol. The transcriptome for growth of APCKJ1 on 2′-FL, as compared 
to a lactose control, was also obtained by the same method. Likewise, global gene transcription was determined 
during log-phase growth of recombinant strain B. breve UCC2003-fumA1fumST1T2 in mMRS supplemented 
with either 2′-FL or lactose. The obtained transcriptome was compared to that determined for log-phase B. breve 
UCC2003-fumA1fumST1T2 cells when grown in mMRS supplemented with ribose.
Microarrays containing oligonucleotides representing each of the 1864 identified open reading frames 
(ORFs) on the genome of B. breve UCC2003, or each of the 2110 identified ORFs on the genome of B. kashi-
wanohense APCKJ1, were designed and obtained from Agilent Technologies (Palo Alto, Ca., USA). Methods 
for cell disruption, RNA isolation, RNA quality control, complementary DNA synthesis and labelling were per-
formed as described previously80. Labelled cDNA was hybridized using the Agilent Gene Expression hybridiza-
tion kit (part number 5188-5242) as described in the Agilent Two-Colour Microarray-Based Gene Expression 
Analysis v4.0 manual (publication number G4140-90050). Following hybridization, microarrays were washed in 
accordance with Agilent’s standard procedures and scanned using an Agilent DNA microarray scanner (model 
G2565A). Generated scans were converted to data files with Agilent’s Feature Extraction software (Version 9.5). 
DNA-microarray data were processed as previously described81–83. Differential expression tests were performed 
with the Cyber-T implementation of a variant of the student t-test84.
DnA Manipulations. Chromosomal DNA was isolated from B. breve UCC2003 and B. kashiwanohense 
APCKJ1 as previously described85. Plasmid DNA was isolated from E. coli, L. lactis and B. breve using the Roche 
High Pure Plasmid Isolation kit (Roche Diagnostics, Basel, Switzerland). An initial lysis step was performed 
using 30 mg ml−1 of lysozyme for 30 minutes at 37 °C prior to plasmid isolation from L. lactis, B. breve or B. 
kashiwanohense. DNA manipulations were essentially performed as described previously79. Restriction enzymes 
and T4 DNA ligase were used according to the supplier’s instructions (Roche Diagnostics, Basel, Switzerland). 
Synthetic single stranded oligonucleotide primers used in this study (Table S4) were synthesized by Eurofins 
(Ebersberg, Germany). Standard PCRs were performed using Extensor Hi-Fidelity PCR Master Mix (Thermo 
Scientific, Waltham, United States) or Q5 High-Fidelity 2X Mastermix (New England BioLabs, Herefordshire, 
United Kingdom) in a Life Technologies Pro-FLex PCR System (Thermo Scientific, Waltham, United States). 
PCR products were visualized by ethidium bromide staining following agarose gel electrophoresis (1% agarose). 
B. breve colony PCR reactions were performed as described previously86. PCR fragments were purified using 
the Roche high Pure PCR purification kit, while plasmid DNA was isolated using the Roche High Pure Plasmid 
Isolation kit (Roche Diagnostics, Basel, Switzerland). Plasmid DNA was introduced into E. coli by electroporation 
as described previously79. B. breve UCC200376 and L. lactis87 were transformed by electroporation according to 
published protocols. The correct fragment orientation and integrity of all plasmid constructs (see also below) 
were verified by DNA sequencing, performed at Eurofins (Ebersberg, Germany).
Construction of overexpression vectors, protein overproduction and purification. For 
the construction of plasmids pNZ-FucA1 and pNZ-FucA2, DNA fragments encompassing the predicted 
fucosidase-encoding genes fumA1 (corresponding to BKKJ1_2069) or fum2 (corresponding to BKKJ1_2070) 
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were generated by PCR amplification from chromosomal DNA of B. kashiwanohense APCKJ1 using Q5 
High-Fidelity DNA polymerase and the primer combinations 2069F and 2069R, or 2070F and 2070R, respectively 
(Table S4). An in-frame N-terminal His10-encoding sequence was incorporated into the forward primers 2069F 
and 2070F to facilitate downstream protein purification. The generated amplicons were digested with SmaI and 
XbaI, and ligated into the ScaI and XbaI-digested, nisin-inducible translational fusion plasmid pNZ815088. The 
ligation mixtures were introduced into L. lactis NZ9000 by electrotransformation and transformants were then 
selected based on chloramphenicol resistance. The plasmid content of a number of Cm-resistant transformants 
was screened by restriction analysis and the integrity of positively identified clones was verified by sequencing.
Nisin-inducible gene expression and protein overproduction was performed as described previously89–91. In 
brief, 400 ml of M17 broth supplemented with 0.5% (wt/vol) glucose was inoculated with a 2% inoculum of a par-
ticular L. lactis strain, followed by incubation at 30 °C until an OD600nm of 0.5 was reached, at which point protein 
expression was induced by addition of cell-free supernatant of a nisin-producing strain92, followed by continued 
incubation for a further 2 hours. Cells were harvested by centrifugation and protein purification achieved as 
described previously90. Protein samples were dialysed into 20 mM morpholinepropanesulfonic acid (MOPS) (pH 
7.0) buffer using Merck Amicon Ultra-15 Centrifugal Filter Units and stored at 4 °C. Protein concentrations were 
determined using the Bradford method93.
Assay of individual and combined fucosidase activities. The individual or sequential hydrolytic activ-
ities specified by FumA1 and FumA2 were determined essentially as described previously89, using either 2′-FL 
or 3-FL as a substrate. Briefly, a 50 μl volume of each purified protein (protein concentration of 0.5 mg/ml) was 
added to 20 mM MOPS (pH 7.0) buffer and 1 mg ml−1 (wt/vol) of one of the above-mentioned sugars in a final 
volume of 1 ml, followed by incubation for 24 hours at 37 °C. In order to determine enzyme affinity, each enzyme 
was incubated individually or in combination, with 2′-FL or 3-FL, as described above, with 200 μl samples taken 
at 20 minutes, 1 hour, 4 hours and 24 hours. All samples were subject to a final enzyme denaturation step at 85 °C 
for 15 minutes, before storage at −20 °C.
HpAec-pAD analysis. For HPAEC-PAD analysis, a Dionex (Sunnyvale, CA) ICS-3000 system was used. 
Carbohydrate fractions from the above-mentioned hydrolysis assays (25 μl aliquots) were separated on a 
CarboPac PA1 analytical-exchange column (dimensions, 250 mm by 4 mm) with a CarboPac PA1 guard column 
(dimensions, 50 mm by 4 mm) and a pulsed electrochemical detector (ED40) in PAD mode (Dionex). Elution 
was performed at a constant flow-rate of 1.0 ml/min at 30 °C using the following eluents for the analysis: eluent 
A, 200 mM NaOH; eluent B, 100 mM NaOH plus 550 mM Na acetate; eluent C, Milli-Q water. The following 
linear gradient of sodium acetate was used with 100 mM NaOH: from 0 to 50 min, 0 mM; from 50 to 51 min, 
16 mM; from 51 to 56 min, 100 mM; from 56 to 61 min, 0 mM. Chromatographic profiles of standard carbohy-
drates were used for comparison of the results of their breakdown by FumA1 or FumA2 proteins. Chromeleon 
software (version 6.70; Dionex Corporation) was used for the integration and evaluation of the chromatograms 
obtained. A 1 mg/ml stock solution of each of the carbohydrates, as well as their putative breakdown products 
(where available) used as reference standards was prepared by dissolving the particular sugar in Milli-Q water. 
Chromatographic profiles of mMRS containing standard carbohydrates were used for comparison of the results of 
their fermentation by B. kashiwanohense APCKJ1. mMRS containing 1% of 2′-FL or 3-FL, as well as their putative 
breakdown products (where available) used as reference standards.
Generation of recombinant B. breve strains. DNA fragments encompassing fumA1 (correspond-
ing to locus tag BKKJ1_2069); and fumS, fumT1 and fumT2 (corresponding to locus tags BKKJ1_2076-2078, 
including the presumed promoter-containing region located upstream of BKKJ1_2078; this fragment was 
designated fumST1T2) were generated by PCR amplification from B. kashiwanohense APCKJ1 using Q5 
High-Fidelity Polymerase (New England BioLabs, Herefordshire, UK) and primer pairs 2069pNZ44F and 
2069pNZ44R, and 2076-78pCB1.2F and 2076-78pBC1.2R, respectively (primers are listed in Table S4. The 
resulting fumA1-encompassing fragment was digested with KpnI and XbaI, and ligated to the similarly digested 
pNZ44-strR94. The ligation mixture was introduced into E. coli EC101 by electrotransformation and trans-
formants were selected based on streptomycin resistance. Transformants were checked for plasmid content using 
colony PCR, restriction analysis of plasmid DNA, and verified by sequencing. Plasmids pNZ44-fumA1-strR and 
pNZ44-strR were introduced into E. coli EC101 harbouring pNZ-M.BbrII-M.BbrIII by electroporation, as previ-
ously described86, and transformants were selected based on Cm and Strep resistance. Methylation of the plasmid 
complement of transformants by the M.BbrIII (an isoschizomer of a methylase corresponding to the PstI recog-
nition site) was confirmed by their observed resistance to PstI restriction86. Methylated pNZ44-fumA1-strR was 
introduced by electrotransformation into B. breve UCC2003 and transformants were selected based on strepto-
mycin resistance, generating B. breve strain UCC2003-fumA1. The fucST1T2 fragment was digested with XmaI 
and XbaI, and ligated to similarly digested pBC1.2 to generate pBC1.2-fucST1T2. The ligation mixture was intro-
duced into E. coli EC101 by electrotransformation and transformants selected based on chloramphenicol resist-
ance. Transformants were checked for plasmid content using colony PCR, restriction analysis of plasmid DNA, 
and verified by sequencing. Plasmid pBC1.2-fucST1T2 was introduced into B. breve UCC2003-fumA1 by electro-
transformation and transformants were selected based on streptomycin and chloramphenicol resistance, gener-
ating strain B. breve UCC2003-fumA1-fucST1T2. In addition, the ‘empty’ cloning vector pBC1.2 was introduced 
into strain B. breve UCC2003-fumA1 (to generate B. breve UCC2003-fumA1-pBC1.2), while ‘empty’ cloning 
vector pNZ44-strR was introduced into strain B. breve UCC2003-fucST1T2 (to generate B. breve UCC2003-fumS
T1T2-pNZ44-strR), in both cases to serve as negative controls. All plasmids and strains are listed in Table S3.
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Sample preparation for nMR analysis. The culture media samples were thawed, vortexed and allowed 
to stand for 10 min at room temperature. To 540 μl of culture media, 60 μl of a 1.5 M KH2PO4 buffer (pH 7.4, 
100% of deuterium oxide (D2O), 2 mM sodium azide and 1% of TSP (3-trimethylsilyl-[2,2,3,3,-2H4]-propionic 
acid sodium salt) was added. The mixture was centrifuged at 18,000 × g at 4 °C for 5 s. An aliquot of 580 μL of 
the supernatant was transferred into a 5 mm outer diameter NMR tube. The samples analysed were the cell-free 
supernatants of B. kashiwanohense APCKJ1, wild type B. breve UCC2003 or B. breve UCC2003-fumA1-fucST1T2 
following 24 h growth in mMRS with 0.05% cysteine-HCL and 1% lactose, L-fucose, 2′-FL or 3-FL. Samples of 
uninoculated media, containing the respective sugars, as well as without any added substrate, were also analysed 
as controls.
nMR spectroscopy and data pre-processing. NMR analysis was performed at 300 K on a Bruker 
800 MHz spectrometer equipped with a 5 mm CPTCI 1H-13C/15N/D Z-gradient cryoprobe, and automated tun-
ing and matching. 1H NMR spectra were acquired using standard one-dimensional pulse sequence, with water 
presaturation (noesygppr1d sequence) during both the relaxation delay (RD = 4 s) and mixing time (τm = 10 ms). 
The receiver gain was set to 16, and acquisition time to 2.73 s for all experiments. Each culture media spectrum 
was acquired using 4 dummy scans, 32 scans and 64 K data-points with a spectral window set to 20 ppm. Prior to 
Fourier Transformation, each free induction decay (FID) was multiplied by an exponential function correspond-
ing to a line broadening of 0.3 Hz. 1H NMR spectra were manually phased, baseline corrected and digitized over 
the range δ −0.5 to 11, and imported into MATLAB (2014a, MathWorks, Natick, U.S.). FIDs were referenced to 
TSP at δ 0.0 ppm. Spectral regions containing residual water (δ 4.69 to 5.18), TSP (δ −0.50 to 0.77), and noise 
(δ 10.26 to 11.00) were removed prior to probabilistic quotient normalization95. Principal component analysis 
(PCA) was applied to the processed Pareto-scaled NMR data using SIMCA software (v. 14.1; Umetrics, Sweden). 
This model was validated by a 7-fold cross-validation.
Identification of metabolites. Metabolites have signals at specific positions in the 1D 1H NMR frequency 
domain spectrum and can have multiple peaks providing a fingerprint for each molecule. The multiplicities, 
chemical shifts and peak area integration of resonance signals were used for structural identification of metabo-
lites. 2D Homonuclear 1H–1H Total Correlation SpectroscopY (TOCSY) and 1H J-resolved (JRES) experiments 
were acquired for a representative sample, to confirm the presence of metabolites. TOCSY spectra of selected 
samples were acquired using the MLEV17 spin-lock scheme and a spectral width of 12 KHz in both dimensions 
and a mixing time of 60 ms. 32 transients per increment (16 dummy scans) were collected into 452 increments 
with a relaxation delay of 2 s and acquisition time of 0.34 s. The spectrum was processed into a resolution of 16k 
(F2) and 1k (F1) using a QSINE function. A JRES spectrum was acquired for the same samples using 8 scans (16 
dummy scans) per increment and 80 increments with an acquisition time of 0.41 s, and a relaxation delay of 2 s. 
JRES spectra were processed using a SINE window function in both dimensions with SSB = 0 and a resolution of 
16k (F2) and 256 (F1). The peaks were subsequently tilted by 45° and symmetrised. Databases such as the Human 
Metabolome Data Base (HMDB; http://hmdb.ca/) or the Biological Magnetic Resonance Data Bank (BMRB; 
http://www.bmrb.wisc.edu) were used for confirmation of assignments. Metabolite concentrations were calcu-
lated relative to the CH3 signal of alanine which was consistent for all samples and remained unmodified by any 
of the bacterial strains.
Bioinformatic analysis. Sequences of proteins identified as upregulated when B. kashiwanohense APCKJ1 
was grown on 2′-FL as the sole carbon source were used to search for homologs across type strains of all available 
Bifidobacterium species, using BLASTP71 at default settings. On-line available genomic data sets of bifidobacteria 
were first retrieved from the NCBI website (http://www.ncbi.nlm.nih.gov) and aligned using an all-vs-all BLASTP 
approach96, using cut-off values of 50% of similarity across 50% of protein length and a 0.0001 e-value as a sig-
nificance for the identification of homologous proteins across all available Bifidobacterium species. The resulting 
alignment was subsequently clustered in Markov Cluster Algorithm (MCL) families of orthologous genes using 
the mclblastline algorithm96. The resulting output was used to first build a presence/absence binary matrix, and 
then the genes of interest were selected and represented in a heatmap employing a code colour grading that rep-
resents the degree of sequence similarity, with species ordered by origin of isolation. The products of the genes 
with locus tags BKKJ1_2072 (designated here as fumF and encoding a putative L2-keto-deoxy-fuconate aldolase), 
BKKJ1_2073 (fumD encoding a predicted L-fuconolactone hydrolase), BKKJ1_2074 (fumC encoding a putative 
L-fucose dehydrogenase) and BKKJ1_2075 (fumE predicted to specify a L-fuconate dehydratase) were selected 
as key enzymes of the fucose utilisation pathway in B. kashiwanohense APCKJ1. A fucose utilisation cluster was 
established as present across bifidobacterial genomes when all the four genes fumF, fumD, fumC and fumE were 
found located within the same genomic region with an average similarity of 70% of the four genes at protein level. 
Automatic protein annotations of the identified clusters were manually checked using the information retrieved 
from alternative databases such as Pfam (http://pfam.xfam.org) and KEGG (http://www.genome.jp/kegg/). The 
sequence similarity of these genes and their homologs in bifidobacterial genomes were represented in a heatmap. 
The identified fucose utilisation clusters identified in B. longum subsp. infantis ATCC 15697, B. pseudocatenula-
tum DSM 20438 and B. breve UCC2003 were directly compared and represented in a locus homology map.
Protein sequences of eighty three GH29 and GH95 α-fucosidases were retrieved from the Cazy (http://
www.cazy.org/Glycoside-Hydrolases.html) and GenBank (https://www.ncbi.nlm.nih.gov/genbank) databases. 
Phylogenetic inference was performed on the eighty three α-fucosidases, with the E. coli K-12 DnaA protein 
(b3702) as an outgroup, using the MEGA7 suite (http://www.megasoftware.net/). Protein sequence alignments 
were performed using the Muscle module available within MEGA7, and the resulting phylogenetic tree was built 
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using the neighbour joining method based on a statistical assessment of 1000 bootstrap replicates. Finally, the 
iTOL viewer (https://itol.embl.de) was employed in order to visualize and produce the final tree.
Ethics approval and consent to participate. The infant faeces used in this study were collected as part 
of the INFANTMET study cohort. Mothers were approached for consent between February 2012 and May 2014 
in Cork University Maternity Hospital, with ethical approval provided by the Cork University Hospital Research 
Ethics Committee. Ethical approval reference: ECM (w) 07/02/2012.
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The genome sequence of B. kashiwanohense APCKJ1 was deposited at the GenBank under Accession No. 
CP026729. The microarray data obtained in this study have been deposited in NCBI’s Gene Expression Omnibus 
database and are accessible through GEO Series Accession Number GSE107439.
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